Abstract
Background
In 2021 we launched the BronchStart study, which collected information on 17,899 presentations in children with serious respiratory tract infections following the release of lockdown restrictions. Our study informed the Joint Committee on Vaccination and Immunisation’s decision to recommend the introduction maternal respiratory syncytial virus (RSV) vaccination, which was introduced in the United Kingdom in August/September 2024.
Study question
We modified our original protocol to conduct a United Kingdom-wide assessment of maternal vaccination against RSV.
Methods and likely impact
We will conduct a multi-centre study, utilising the PERUKI network used in the original BronchStart study, to assess the effectiveness of maternal vaccination using a test-negative study design. We will gather detailed clinical information on children admitted with bronchiolitis in the post-RSV vaccination era, and understand possible reasons for incomplete vaccine uptake.
In 2021 we launched the BronchStart study, which collected information on 17,899 presentations to hospital in children with serious respiratory tract infections following the release of lockdown restrictions in the United Kingdom. We found that the most common cause of these presentations was a virus called respiratory syncytial virus (RSV). Our study informed the the subsequent decision to introduce a vaccine against this virus, given to pregnant mothers to protect their baby after birth. This vaccine was introduced in August/September of 2024 in the United Kingdom. We decided to use the same network that had performed the original BronchStart study to perform a study to look at the effectiveness of this new maternal vaccine. This new sub-study, called BronchStop, will collect detailed information on babies admitted to hospital with serious respiratory disease, and interview mothers to identify reasons why they might have chosen not to receive the RSV vaccine whilst pregnant.
In 2021 we launched the BronchStart study, which collected information on 17,899 presentations in children with serious respiratory tract infections following the release of lockdown restrictions. Our study informed the Joint Committee on Vaccination and Immunisation’s decision to recommend the introduction maternal respiratory syncytial virus (RSV) vaccination, which was introduced in the United Kingdom in August/September 2024.
Study question
We modified our original protocol to conduct a United Kingdom-wide assessment of maternal vaccination against RSV.
Methods and likely impact
We will conduct a multi-centre study, utilising the PERUKI network used in the original BronchStart study, to assess the effectiveness of maternal vaccination using a test-negative study design. We will gather detailed clinical information on children admitted with bronchiolitis in the post-RSV vaccination era, and understand possible reasons for incomplete vaccine uptake.
In 2021 we launched the BronchStart study, which collected information on 17,899 presentations to hospital in children with serious respiratory tract infections following the release of lockdown restrictions in the United Kingdom. We found that the most common cause of these presentations was a virus called respiratory syncytial virus (RSV). Our study informed the the subsequent decision to introduce a vaccine against this virus, given to pregnant mothers to protect their baby after birth. This vaccine was introduced in August/September of 2024 in the United Kingdom. We decided to use the same network that had performed the original BronchStart study to perform a study to look at the effectiveness of this new maternal vaccine. This new sub-study, called BronchStop, will collect detailed information on babies admitted to hospital with serious respiratory disease, and interview mothers to identify reasons why they might have chosen not to receive the RSV vaccine whilst pregnant.
| Original language | English |
|---|---|
| Article number | 120 |
| Journal | Wellcome Open Research |
| Volume | 6 |
| DOIs | |
| Publication status | Published - 18 Dec 2024 |
Access to Document
- Update to: Study Pre-protocol for “BronchStart - the impact of the COVID-19 pandemic on the timing, age and severity of Respiratory Syncytial Virus (RSV) emergency presentations; a multi-centre prospective observational cohort study” [version 4; peer review: 3 approved, 1 approved with reservations]
Copyright 2024 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.